JP2020520374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520374A5 JP2020520374A5 JP2019563766A JP2019563766A JP2020520374A5 JP 2020520374 A5 JP2020520374 A5 JP 2020520374A5 JP 2019563766 A JP2019563766 A JP 2019563766A JP 2019563766 A JP2019563766 A JP 2019563766A JP 2020520374 A5 JP2020520374 A5 JP 2020520374A5
- Authority
- JP
- Japan
- Prior art keywords
- stat5
- compound
- composition according
- body weight
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 19
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 claims 14
- 230000037396 body weight Effects 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 238000010362 genome editing Methods 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims 7
- 229960003634 pimozide Drugs 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 6
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 229960002715 nicotine Drugs 0.000 claims 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 102000014400 SH2 domains Human genes 0.000 claims 1
- 108050003452 SH2 domains Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003701 histiocyte Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506698P | 2017-05-16 | 2017-05-16 | |
| US62/506,698 | 2017-05-16 | ||
| PCT/US2018/031217 WO2018213027A1 (en) | 2017-05-16 | 2018-05-04 | Compositions and methods for treating rheumatoid arthritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520374A JP2020520374A (ja) | 2020-07-09 |
| JP2020520374A5 true JP2020520374A5 (https=) | 2021-07-26 |
| JP7493939B2 JP7493939B2 (ja) | 2024-06-03 |
Family
ID=64274562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563766A Active JP7493939B2 (ja) | 2017-05-16 | 2018-05-04 | 関節リウマチの治療用組成物および治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11612595B2 (https=) |
| EP (1) | EP3628006A4 (https=) |
| JP (1) | JP7493939B2 (https=) |
| KR (1) | KR102707515B1 (https=) |
| CN (2) | CN111032041A (https=) |
| AU (1) | AU2018270772B2 (https=) |
| CA (1) | CA3063100A1 (https=) |
| TW (1) | TWI850196B (https=) |
| WO (1) | WO2018213027A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7527662B2 (ja) * | 2019-04-09 | 2024-08-05 | ジェネラス バイオファーマ リミテッド | ピモジドとメトトレキサートの医薬組成物、及びその使用 |
| EP3960175A4 (en) * | 2019-04-26 | 2023-01-11 | Generos Biopharma Ltd. | USE OF A COMPOUND IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF ATHEROSCLEROSIS |
| CA3133733A1 (en) * | 2019-04-30 | 2020-11-05 | Xin-Yuan Fu | Compounds for treating inflammation induced autoimmune skin diseases and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7649098B2 (en) | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
| US8138339B2 (en) * | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| ES2547916T3 (es) * | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| ES2731609T3 (es) * | 2012-11-01 | 2019-11-18 | Univ California | Polipéptidos ERFE y eritroferrona y métodos de regulación del metabolismo del hierro |
| AU2014339897A1 (en) * | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| CA2962757C (en) * | 2014-09-26 | 2022-03-22 | National University Of Singapore | Methods and compositions for modulating th-gm cell function |
-
2018
- 2018-05-04 JP JP2019563766A patent/JP7493939B2/ja active Active
- 2018-05-04 CN CN201880045404.9A patent/CN111032041A/zh active Pending
- 2018-05-04 EP EP18801432.8A patent/EP3628006A4/en active Pending
- 2018-05-04 CN CN202311267811.3A patent/CN117085015A/zh active Pending
- 2018-05-04 CA CA3063100A patent/CA3063100A1/en active Pending
- 2018-05-04 KR KR1020197036560A patent/KR102707515B1/ko active Active
- 2018-05-04 AU AU2018270772A patent/AU2018270772B2/en active Active
- 2018-05-04 US US16/613,261 patent/US11612595B2/en active Active
- 2018-05-04 WO PCT/US2018/031217 patent/WO2018213027A1/en not_active Ceased
- 2018-05-16 TW TW107116605A patent/TWI850196B/zh active
-
2023
- 2023-03-27 US US18/126,953 patent/US20230364072A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528655A5 (https=) | ||
| MX2024001849A (es) | Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita. | |
| MX2022011834A (es) | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. | |
| JP2020520374A5 (https=) | ||
| JP2023543299A5 (https=) | ||
| JP2022545005A5 (https=) | ||
| CA2866108C (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| JP2014526492A5 (https=) | ||
| JP2015528471A5 (https=) | ||
| JP2016518437A5 (https=) | ||
| JP2015024998A5 (https=) | ||
| JP2013521303A5 (https=) | ||
| JP2018534286A5 (https=) | ||
| NZ600790A (en) | Combination therapy for copd | |
| JP2015510916A5 (https=) | ||
| JP2011506412A5 (https=) | ||
| CY1123346T1 (el) | Παραγωγα 5-[2-(πυριδιν-2-υλαμινο)-1,3-θειαζολ-5-υλ]-2,3-διυδρο-1η-ισοϊνδολ-1-ονης και χρηση τους ως διπλοι αναστολεις της 3-κινασης φωσφατιδυλοϊνοσιτολης δελτα & γαμμα | |
| JP2015535247A5 (https=) | ||
| JP2016510785A5 (https=) | ||
| JP2014532726A5 (https=) | ||
| JP2016516773A5 (https=) | ||
| JP2010527985A5 (https=) | ||
| MX2022004197A (es) | Inhibidores del factor d del complemento para administracion oral. | |
| IL305952A (en) | Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment | |
| JP2017509611A5 (https=) |